The nondihydropyridine CCBs, including the phenylalkylamines (verapamil-like) and benzothiazepines (diltiazem-like), bind to different sites on the 1 subunit and are less selective for vascular tissue; they have nega- tive chronotropic and dromotropic effects on sinoatrial and atrioventricular nodal conducting tissue and negative ino- tropic effects on cardiomyocytes. The nondihydropyridine CCBs have greater effects on the atrioventricular node than on the sinoatrial node and may predispose to high-degree atrioventricular block in patients with preexisting atrioven- tricular nodal disease or when given with other agents, for example, -blockers, that depress the atrioventricular node. Both CCB subclasses are indicated for the treatment of hypertension and angina pectoris. The antianginal effects of CCBs result from afterload reduction, that is, their ability to decrease SBP, as well as coronary vasodilation and, in the case of nondihydropyridine CCBs, heart rate slowing. CCBs are particularly effective in treating angina caused by coronary spasm, for example, the Prinzmetal variant or 2. Prevention of Cardiovascular Events in Patients With Hypertension and CAD 2.1. Antihypertensive Drugs for the Secondary Prevention of Cardiovascular Events in Patients With CAD Meta-analyses of antihypertensive trials have demonstrated that BP lowering is more important than the particular drug class used in the primary prevention of the complications of hypertension, including IHD. Combination antihypertensive drug therapy is typically needed to achieve and to sustain effective long-term BP control. Thus, there is no evidence to support initiating therapy with any one antihypertensive drug class over another for the primary prevention of IHD. In con- trast, for secondary protection in individuals with underlying comorbid illnesses such as IHD, CKD, or recurrent stroke, not all drug classes have been proven to confer optimal or even the same level of benefit. 